The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. You should consider whether you understand how CFDs work and can afford the risks. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. What is the dividend yield for AbbVie? This indicates that the company will be able to sustain or increase its dividend. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. AbbVie has 5 focus areas for its research and products. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. All rights reserved. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. on the strength of its future rather than present portfolio. Our daily ratings and market update email newsletter. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. I am not receiving compensation for it (other than from Seeking Alpha). Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. What is a Good Dividend Yield? Receive regular, detailed analysis focused on biotech and healthcare stocks. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. This suggests a possible upside of 3.2% from the stock's current price. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. I have no business relationship with any company whose stock is mentioned in this article. View ABBV analyst ratings or view top-rated stocks. The median. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. AbbVie stock is one of the most well-known pharmaceutical companies. I wrote this article myself, and it expresses my own opinions. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. Kateryna Onyshchuk/iStock via Getty Images. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. See what's happening in the market right now with MarketBeat's real-time news feed. I am not receiving compensation for it (other than from Seeking Alpha). The average price target represents a 6.33% change from the last price of $153.90. Forecast . The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. . AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. Compare Top Brokerages Here. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Identify stocks that meet your criteria using seven unique stock screeners. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Price target. The analysts 12-month consensus ABBV stock price target was $159.75. On average, they predict the company's stock price to reach $161.12 in the next year. Finally, AbbVie was able to raise its financial . All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. The company reported its first revenue for Botox competitor Daxxify. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. What is AbbVie's stock price forecast for 2023? AbbVie has a P/B Ratio of 15.97. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.".
How To Calculate Coefficient Of Coincidence And Interference,
Does Nomberry Sell Authentic Items,
Articles A